%0 Journal Article %T Abiraterone plus prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer: is a question of quality? %A Lavacchi, Daniele %A Mini, Enrico %A Roviello, Giandomenico %J AME Medical Journal %D 2019 %B 2019 %9 %! Abiraterone plus prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer: is a question of quality? %K %X Khalaf et al . (1) presented a sub-sequent analysis of a previously conducted phase II trial aimed to compare activity of abiraterone acetate + prednisone (AA + P) versus enzalutamide (E) in more than 200 patients with treatment-naive metastatic castration-resistant prostate cancer (2). In this study, the authors found that AA + P and E showed similar activity in terms of time to prostate-specific antigen (PSA), clinical, or radiographic progression (2). %U https://amj.amegroups.org/article/view/4923 %V 4 %P %@ 2520-0518